このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Role of NSI in Differentiating Between Mild Traumatic Brain Injury And Behavioral Health Conditions

2017年5月12日 更新者:VA Eastern Colorado Health Care System

Differentiating Between Mild Traumatic Brain Injury And Behavioral Health Conditions: The Role of The Neurobehavioral Symptom Inventory

The purpose of this study is to examine differences in post-concussive (PC) symptom endorsement among four groups of Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans: those with a history of target, service-related, mild traumatic brain injury (mTBI) and co-occurring posttraumatic stress disorder (PTSD) (Group 1); those with a history of target, service-related, mTBI only (Group 2); those with PTSD only (Group 3); and those with no history of target, service-related, mTBI or PTSD (Group 4) by examining scores on the Neurobehavioral Symptom Inventory (NSI). Support for this study is provided by previous research highlighting the complex relationship between mTBI, PTSD and subsequent PC symptom endorsement (Brenner et al. 2010; Terrio et al, 2009).

HYPOTHESES ARE AS FOLLOWS:

  1. Individuals with a history of target, service-related, mTBI only (Group 2) and individuals with PTSD only (Group 3) each will report significantly more PC symptoms, as measured by NSI total scores, when compared to those with no history of service-related mTBI or PTSD (Group 4).
  2. Individuals with co-occurring target, service-related, mTBI history and PTSD (Group 1) will report significantly more PC symptoms, as measured by total NSI scores, than either those with target, service-related, mTBI only (Group 2) or those with PTSD only (Group 3).

調査の概要

詳細な説明

Archival data will be collected from all OEF/OIF Veterans who were seen in the VA ECHCS TBI Clinic by Nancy Cutter, M.D. and her team between January 1, 2009 and December 31, 2010. Electronic Medical Record (EMR) progress note titles "OEF/OIF TBI 2nd Level Evaluation Consult Report" and "TBI Consult Report" will be used to identify potential subjects.

Power is based on the primary hypothesis that those with PTSD only (Group 3) and those with target, service-related mTBI only (Group 2) will have significantly more PC symptom reporting than those with no history of target, service-related mTBI or PTSD (Group 4). Belanger et al. (2010) reported a standard deviation of 15.3 on the NSI total score in a sample of 134 mTBI subjects. Assuming variability similar to the Belanger study, a significance level of 0.025 to correct for the two comparisons and 80% power, 180 subjects per group will detect a clinically significant difference of 5 points. For simplicity, this was calculated using a two-sided, two-sample t-test. Given that we are modeling all four groups together, pooled standard error estimates will be used, which will result in slightly higher power.

All analyses will assume a two-sided test of hypothesis with an overall significance level of 0.05, unless otherwise noted, and will be performed in either Statistical Analysis Software (SAS) v9.2 or above (SAS Institute, Inc., Cary, NC).

Demographic characteristics will be reported as means and standard deviations; medians and ranges; and proportions, as appropriate. Likewise, characteristics will be compared between the four aforementioned subject groups using Analysis of Variance (ANOVA), chi-square tests and/or nonparametric tests as appropriate.

Hypothesis 1: An ANOVA with reference cell coding will be utilized to model NSI total score as a function of the four groups (Group 1: Individuals with co-occurring target, service-related, mTBI and PTSD; Group 2: those with target, service-related, mTBI only; Group 3: those with PTSD only; and Group 4: those with no history of target, service-related, mTBI or PTSD). Potential confounders will then be assessed individually by adding them to the model with the groups. If any of the group parameter estimates changes by more than 10% with the inclusion of the potential confounder, the variable will be utilized in the final model. Once the final model is determined, a contrast will be set up within the model to test (1) PTSD only vs. Neither and (2) target, service-related, mTBI only vs. Neither, a Bonferroni correction will be employed such that the significance level will be adjusted to 0.025 for these two primary tests. Estimated mean differences will be reported with 95% CIs. Potential confounding variables to be considered are: age; gender; total number of deployments; time since last deployment; time since earliest documented mTBI; time since target, service-related, mTBI; and total number of mTBIs.

Hypothesis 2: Within the same final model above, a contrast will be used to test (1) those with co-occurring target, service-related, mTBI and PTSD vs. PTSD only and (2) those with co-occurring target, service-related, mTBI and PTSD vs. target, service-related, mTBI only.

研究の種類

観察的

入学 (実際)

887

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Colorado
      • Denver、Colorado、アメリカ、80220
        • VA Eastern Colorado Health Care System

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~60年 (大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Archival data will be collected from all OEF/OIF Veterans who were seen in the VA ECHCS TBI Clinic by Nancy Cutter, M.D. and her team between January 1, 2009 and December 31, 2010. Electronic Medical Record (EMR) progress note titles "OEF/OIF TBI 2nd Level Evaluation Consult Report" and "TBI Consult Report" will be used to identify potential subjects.

説明

Inclusion criteria for all groups includes:

  • Veteran must be between the ages of 18 to 60
  • Veteran must have at least one OEF/OIF deployment
  • Veteran must have received an OEF/OIF TBI 2nd Level Evaluation though the VA ECHCS TBI Clinic

Specific inclusion/exclusion criteria for each group are as follows:

Inclusion Criteria:

Group 1: (Both) Co-Occurring PTSD and target, service-related, mTBI

PTSD:

  • Clinician confirmed PTSD diagnosis and continuous documentation of symptoms related to PTSD diagnosis within 1 year prior to being seen in the TBI Clinic, or
  • Clinician confirmed PTSD diagnosis within 1 year prior to being seen in the TBI Clinic, or
  • Clinician confirmed PTSD diagnosis within 60 days after being seen in TBI Clinic
  • Target, service-related, mTBI
  • Veterans with clinician confirmed target, service-related, mTBI per OEF/OIF TBI 2nd Level Evaluation Consult Report note in EMR

Group 2: (mTBI only) History of target, service-related, mTBI but with no diagnosis of PTSD

  • PTSD:
  • Veterans with no history of clinician confirmed PTSD diagnosis, or
  • Veterans with previous clinician confirmed PTSD diagnosis , but without continuous documentation of PTSD symptoms within 1 year prior to being seen in the TBI clinic
  • Target, service-related, mTBI
  • Veterans with clinician confirmed target, service-related, mTBI per OEF/OIF TBI 2nd Level Evaluation Consult Report note in EMR

Group 3: (PTSD only) No history of target, service-related, mTBI but with a diagnosis of PTSD

  • PTSD:
  • Clinician confirmed PTSD diagnosis and continuous documentation of symptoms related to PTSD diagnosis within 1 year prior to being seen in the TBI Clinic, or
  • Clinician confirmed PTSD diagnosis within 1 year prior to being seen in the TBI Clinic, or
  • Clinician confirmed PTSD diagnosis within 60 days of being seen in TBI Clinic
  • TBI:
  • Veterans with no history of clinician confirmed diagnosis of target, service-related, mTBI
  • Veterans with clinician confirmed mTBI prior to service and without continuous documentation of related symptoms within 1 year of being seen in the TBI Clinic

Group 4: (Neither) No history of target, service-related, mTBI and no diagnosis of PTSD

  • PTSD:
  • Veterans with no history of clinician confirmed PTSD diagnosis, or
  • Veterans with previous clinician confirmed PTSD diagnosis , but without continuous documentation of PTSD symptoms within 1 year of being seen in the TBI clinic
  • TBI:
  • Veterans with no clinician confirmed diagnosis of target, service-related, mTBI

Exclusion Criteria:

  • Those not meeting inclusion criteria as listed above, and
  • Veterans with any history of clinician confirmed moderate or severe TBI, and
  • Veterans with no NSI in TBI Consult Report note in EMR
  • Veterans with documentation of any neurological event or disorder other than mTBI
  • Veterans with positive brain imaging

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:コホート
  • 時間の展望:回顧

コホートと介入

グループ/コホート
介入・治療
OEF/OIF Veterans
Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans
This retrospective data analysis will rely on data obtained from chart review.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Neurobehavioral Symptom Inventory
時間枠:1 day (NSI was administered 1 time during clinical visit and documented in EMR as described below)

The Neurobehavioral Symptom Inventory (NSI; Cicerone & Kalmar, 1995)is a 22-item self-report measure of PC symptoms recommended for use among military personnel by the Department of Defense (DoD). Subject responses to all 22 items will be extracted from each subject's TBI Consult Report note provided in her/his Electronic Medical Record (EMR).

Estimated time to collect all data from this retrospective chart review is 1 year.

1 day (NSI was administered 1 time during clinical visit and documented in EMR as described below)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Gina Signoracci, Ph.D.、VA Eastern Colorado Health Care System

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2011年3月1日

一次修了 (実際)

2015年5月1日

研究の完了 (実際)

2015年5月1日

試験登録日

最初に提出

2011年12月9日

QC基準を満たした最初の提出物

2011年12月30日

最初の投稿 (見積もり)

2012年1月2日

学習記録の更新

投稿された最後の更新 (実際)

2017年5月15日

QC基準を満たした最後の更新が送信されました

2017年5月12日

最終確認日

2012年12月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する